Novel Postneoadjuvant Prognostic Breast Cancer Staging System
David J. Winchester(City of Hope), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Stephen B. Edge(American Society of Clinical Oncology), Lavisha Singh(NorthShore University HealthSystem), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Jennifer K. Plichta(Cancer Institute (WIA)), Mariana Chávez‐MacGregor(The University of Texas MD Anderson Cancer Center), Jennifer F. De Los Santos(Washington University in St. Louis), Donald L. Weaver(University of Vermont), Emily F. Conant(University of Pennsylvania), Elena Provenzano(University of Cambridge), Kilian Salerno(Cleveland Clinic), William E. Barlow(Cancer Research And Biostatistics), Kimberly H. Allison(Stanford University), Veerle Bossuyt(Harvard University), James L. Connolly(Beth Israel Deaconess Medical Center)
Cited by 6
Related Papers
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k